Iverheal 3mg (Ivermectin): Complete Medical Guide

Iverheal 3mg is a prescription antiparasitic tablet containing Ivermectin as its active ingredient, manufactured by Healing Pharma India Pvt. Ltd. It is indicated for the treatment of parasitic infections affecting the intestinal tract, skin, and eyes. Ivermectin belongs to the macrocyclic lactone class of medications and is included in the World Health Organization’s (WHO) List of Essential Medicines — a recognition reserved for medications considered indispensable to meet the priority healthcare needs of any population. 

Since its approval for human use in 1987, Ivermectin has been administered to hundreds of millions of people worldwide through mass drug administration programmes targeting neglected tropical diseases. In 2015, its co-discoverers — Satoshi Ōmura and William C. Campbell — were awarded the Nobel Prize in Physiology or Medicine for this groundbreaking contribution to global health. In 2023, Ivermectin remained among the most frequently prescribed antiparasitic agents, with over 400,000 prescriptions dispensed in the United States alone. 

Important: Iverheal 3mg is a prescription-only medication. It is not advisable to self-medicate with this drug. Always consult a qualified healthcare provider before commencing treatment. 

What is Iverheal 3mg? 

Iverheal 3mg is the brand name for a 3-milligram oral tablet of Ivermectin produced by Healing Pharma India Pvt. Ltd., a GMP-compliant Indian pharmaceutical manufacturer supplying medications to international markets including the United States, United Kingdom, and Southeast Asia. 

The active compound, Ivermectin, is a semisynthetic derivative of avermectin — a naturally occurring compound produced by the soil bacterium Streptomyces avermitilis, first isolated from a woodland soil sample in Japan in 1970 by microbiologist Satoshi Ōmura. The compound was chemically modified by scientists at Merck & Co. to enhance its potency and safety, giving rise to Ivermectin — comprising 80% 22,23-dihydroavermectin-B1a and 20% 22,23-dihydroavermectin-B1b. 

Iverheal is available in three strengths — 3mg, 6mg, and 12mg — allowing healthcare providers to accurately calibrate dosage according to the patient’s body weight and clinical condition. 

How Does Iverheal 3mg Work? (Mechanism of Action)

Ivermectin exerts its antiparasitic effect through a highly selective mechanism. It binds with high affinity to glutamate-gated chloride ion channels (GluCl) found exclusively in invertebrate nerve and muscle cells. This binding increases the cell membrane’s permeability to chloride ions, causing hyperpolarization of the nerve or muscle cell — resulting in paralysis and death of the parasite 

Crucially, these glutamate-gated chloride channels do not exist in mammals. This selectivity is the reason Ivermectin is toxic to parasites while being comparatively safe for human use at recommended therapeutic doses. In addition to paralysis, Ivermectin prevents adult female parasites from  producing viable larvae, disrupting the reproductive cycle and long-term parasitic burden. 

Pharmacokinetics

Following oral administration on an empty stomach, Ivermectin is absorbed from the gastrointestinal tract with a half-life of absorption of approximately 0.5 to 2.5 hours. Peak plasma concentration is typically reached within 4 hours of ingestion. The drug begins to clear from the bloodstream after approximately 18 hours; however, it remains pharmacologically active within the intestinal lumen, with metabolites detectable for up to 12 days — particularly significant for the treatment of intestinal strongyloidiasis. Approximately 90% of the drug and its metabolites are excreted via feces, with less than 1% eliminated through urine. Ivermectin is predominantly metabolized in the liver via cytochrome P450 enzymes (primarily CYP3A4). 

Note: Bioavailability increases approximately 2.5-fold when taken with a fatty meal. For strongyloidiasis and onchocerciasis, the drug should be taken on an empty stomach. For scabies and head lice, it may be taken with food to enhance epidermal absorption. 

Uses of Iverheal 3mg 

Iverheal 3mg is prescribed to treat a range of parasitic infections. The following are its primary approved and evidence-supported indications: 

1. Intestinal Strongyloidiasis 

Caused by Strongyloides stercoralis, a parasitic roundworm capable of auto-infection within the human host, strongyloidiasis can be fatal in immunocompromised patients if left untreated. Ivermectin is considered the first-line treatment for this condition, offering superior efficacy over alternatives such as albendazole. A single oral dose of 200 mcg/kg is typically sufficient, with follow-up stool examinations recommended to confirm eradication. 

2. Onchocerciasis (River Blindness) 

Caused by Onchocerca volvulus and transmitted by blackflies along fast-flowing rivers, onchocerciasis is a leading cause of preventable blindness globally. Iverheal 3mg reduces microfilarial load in the skin and eyes, alleviating symptoms including severe pruritus, skin nodules, and progressive vision loss. While it does not eliminate adult worms, it suppresses microfilarial production for 6–12 months per dose. Annual or semi-annual dosing is standard within WHO-supported elimination programmes. 

3. Scabies 

Scabies is caused by the mite Sarcoptes scabiei and results in intensely pruritic skin lesions. Oral Ivermectin is particularly recommended in cases of crusted (Norwegian) scabies, institutional outbreaks, or where topical treatments have failed. Clinical studies suggest a repeat dose 1–2 weeks after the first may improve cure rates. Side effects are reported in fewer than 4% of patients treated for this indication. 

4. Filariasis (Lymphatic Filariasis) 

Transmitted by mosquitoes, lymphatic filariasis is caused primarily by Wuchereria bancrofti. Iverheal 3mg reduces the circulating microfilarial load, limiting disease progression and community-level transmission. It is used within the WHO Global Programme to Eliminate Lymphatic Filariasis, often co-administered with albendazole as part of annual mass drug administration campaigns. Recent evidence supports the synergistic benefit of the ivermectin-albendazole combination, particularly for trichuriasis. 

5. Head Lice (Pediculosis Capitis) 

Oral Ivermectin is an effective option for head lice infestations that have proven resistant to topical treatments. It acts by paralyzing the lice and disrupting their feeding mechanism. A single dose is often effective, though a second dose after 7–10 days may be recommended depending on clinical response. 

6. Cutaneous Larva Migrans 

This skin condition arises from hookworm larvae (primarily Ancylostoma braziliense) that penetrate the skin from contaminated soil. Ivermectin at 200 mcg/kg — administered once daily for 1 to 2 days — is effective at eliminating the migrating larvae responsible for the characteristic serpiginous (snake-like) tracks on the skin surface, as recommended by Médecins Sans Frontières medical guidelines. 

7. Mansonella Infections 

Iverheal 3mg is also used in the treatment of parasitic infections caused by Mansonella ozzardi, Mansonella perstans, and Mansonella streptocerca — filarial worms transmitted through insect bites in tropical endemic regions. 

Available Strengths of Iverheal 

• Iverheal 3mg — for patients with lower body weight (15–24 kg) or as a component of combination dosing 
• Iverheal 6mg — intermediate strength for patients in the 25–35 kg range 
• Iverheal 12mg — for higher body weight patients or conditions requiring stronger dosing 

Dosage and Administration 

The dosage of Iverheal 3mg is determined by the patient’s body weight and the specific parasitic condition being treated. It is essential to follow the exact regimen prescribed by your healthcare provider. The following table summarizes the FDA-approved dosage guidelines for the two primary indications: 

Body Weight (kg)	Strongyloidiasis Dose	Onchocerciasis Dose
15–24 kg	1 tablet (3 mg)	1 tablet (3 mg)
25–35 kg	2 tablets (6 mg)	2 tablets (6 mg)
36–50 kg	3 tablets (9 mg)	3 tablets (9 mg)
51–65 kg	4 tablets (12 mg)	3 tablets (9 mg)
66–79 kg	5 tablets (15 mg)	4 tablets (12 mg)
≥ 80 kg	0.2 mg/kg	0.15 mg/kg

For Scabies: 200 mcg/kg as a single dose; a repeat dose after 7–14 days is recommended for crusted scabies or inadequate response. 

For Cutaneous Larva Migrans: 200 mcg/kg once daily for 1–2 days per MSF clinical guidelines. 

For Immunocompromised Patients (HIV/AIDS): Repeated dosing every 2 weeks may be necessary for strongyloidiasis, as parasite clearance is often incomplete in the absence of a functional immune response. 

Missed Dose 

If a dose of Iverheal 3mg is missed, it is advisable to take it as soon as it is recalled — provided sufficient time remains before the next scheduled dose. If the next dose is imminent, the missed dose should be skipped. Do not take two doses simultaneously to compensate for a missed one, as this increases the risk of adverse effects without added therapeutic benefit. 

Overdose 

In the event of an accidental overdose, discontinue the medication immediately and seek medical attention without delay. Symptoms of Ivermectin overdose may include muscular aches, back pain, extreme fatigue, vomiting, diarrhea, dizziness, hypotension, and in severe cases, neurological effects including disorientation and impaired consciousness. Your healthcare provider will determine appropriate management based on the dose ingested and presenting symptoms. 

How to Take Iverheal 3mg 

• Take on an empty stomach with a full glass of water (approx. 240 mL) for strongyloidiasis and onchocerciasis. 
• For scabies and head lice, taking with food may enhance drug absorption into the skin. 
• Adhere strictly to the schedule and duration prescribed by your healthcare provider. 
• The tablet may be cut or crushed only when specifically advised by your healthcare professional. 
• Carry the medication during travel to maintain continuity of the prescribed treatment schedule. 
• Do not self-adjust doses or discontinue treatment prematurely without consulting a healthcare provider. 

Precautions and Warnings 

Before commencing treatment with Iverheal 3mg, it is essential to disclose your complete medical history to your healthcare provider. The following precautions require particular attention: 

Loa loa Co-infection (Critical Warning) 

Patients who have resided in or travelled to West or Central Africa may be at risk of co-infection with Loa loa, a filarial parasite. Administration of Ivermectin in individuals with high Loa loa microfilarial counts (above 30,000 mf/mL) carries a significant risk of potentially fatal encephalopathy. This is among the most serious contraindications associated with Ivermectin use. Appropriate screening for Loa loa is imperative prior to treatment in all at-risk individuals. 

Allergies 

Inform your healthcare provider of any known allergy to Ivermectin or to the inactive ingredients present in the tablet. Allergic reactions may include skin rash, hives, swelling of the face or throat, and difficulty breathing. Discontinue immediately and seek emergency care if signs of anaphylaxis appear. 

Liver Disease 

Ivermectin is primarily metabolized in the liver via CYP3A4 enzymes. Patients with hepatic impairment should use Iverheal 3mg with caution and under close medical supervision. Periodic liver function testing may be advisable during treatment. 

Immunocompromised Patients 

Patients living with HIV/AIDS or undergoing immunosuppressive therapy may require repeated courses of Iverheal 3mg, as their reduced immune response may result in parasitic persistence or reinfection. Treatment outcomes in this group should be monitored closely through follow-up stool examinations or clinical evaluation. 

Pregnancy 

A 2020 systematic review and meta-analysis published in The Lancet Global Health concluded that there is insufficient evidence to confirm the safety of Ivermectin during pregnancy, with very low certainty of evidence regarding risk of spontaneous abortion, stillbirths, or congenital anomalies. Pregnant women are currently excluded from most community-directed treatment programmes for onchocerciasis. Iverheal 3mg should be avoided during pregnancy — particularly in the first trimester — unless the clinical benefit clearly outweighs potential risk, as determined by a qualified healthcare provider. 

Breastfeeding 

Ivermectin is excreted in breast milk in small quantities. Published pharmacological data indicate low concentrations of the drug are detectable in human breast milk. The therapeutic dose (0.050–0.400 mg/kg single dose) may be administered under medical supervision when clinically necessary, but it is advisable to consult a healthcare provider to evaluate the risk-benefit profile in the context of the individual clinical situation. 

Kidney Disease 

Iverheal 3mg is generally considered lower risk in patients with mild to moderate renal impairment. However, caution is warranted in those with severe kidney disease, and consultation with a healthcare provider is recommended before initiating therapy. 

Asthma and Seizure History 

Patients with a history of asthma or seizure disorders should not use Iverheal 3mg without explicit medical guidance, as the medication may exacerbate these conditions in susceptible individuals. 

Driving and Operating Machinery 

Iverheal 3mg may cause dizziness and drowsiness. It is advisable to refrain from driving or operating heavy machinery until the individual’s response to the medication has been fully assessed. 

Alcohol and Cannabis 

Concurrent use of alcohol or cannabis-derived products during Iverheal 3mg therapy is not advisable, as these substances may potentiate the central nervous system depressant effects of the medication, intensifying dizziness and sedation. 

Side Effects of Iverheal 3mg

Like all medications, Iverheal 3mg may cause side effects in some individuals. Clinical evidence indicates that side effects are reported in fewer than 4% of patients receiving Ivermectin for skin conditions. The nature and severity of these effects may vary depending on the condition treated, the dose administered, and the patient’s individual response.  

Common (Mild) Side Effects — Intestinal Infections 

• Loss of appetite 
• Nausea and vomiting 
• Stomach pain or bloating 
• Diarrhea 
• Dizziness or lightheadedness 
• Drowsiness or fatigue 
• Mild skin itching 

Mazzotti Reaction — Onchocerciasis Treatment 

In approximately 10% of patients treated for onchocerciasis, a Mazzotti reaction may occur — a temporary immunological response triggered by the mass death of microfilariae. Symptoms may include: 

• Joint and limb swelling 
• Mild to moderate fever 
• Skin rash or worsening pruritus 
• Eye redness or mild discomfort 

These reactions are generally self-limiting and do not typically require discontinuation of therapy. However, severe Mazzotti reactions should be reported to a healthcare provider for appropriate management. 

Serious Side Effects — Seek Immediate Medical Attention 

• Neurological effects: severe dizziness, confusion, seizures, encephalopathy, or loss of consciousness 
• Severe ocular effects: significant redness, pain, swelling, intraocular bleeding, or sudden changes in vision 
• Cardiovascular effects: hypotension (low blood pressure), fainting, or rapid heart rate 
• Severe cutaneous reactions: extensive blistering, skin peeling, or signs of Stevens-Johnson syndrome 
• Hepatotoxicity: jaundice (yellowing of skin or eyes), dark urine, or severe right-sided abdominal pain 
• Haematological changes: unexplained bruising, bleeding, or pallor 
• Extreme systemic fatigue: particularly when accompanied by other organ-specific symptoms 

If any serious adverse effects are identified, discontinue Iverheal 3mg and seek emergency medical attention without delay. 

Drug Interactions 

Ivermectin is primarily metabolized by the CYP3A4 hepatic enzyme system. Drugs that inhibit or induce this pathway may alter Ivermectin plasma concentrations, affecting both efficacy and safety. The following drug interactions are clinically significant: 

• Warfarin: Co-administration may potentiate the anticoagulant effect of Warfarin, increasing bleeding risk. Close INR monitoring is essential when these medications are used concurrently. 
• Erythromycin: This macrolide antibiotic is a known CYP3A4 inhibitor and may increase Ivermectin plasma levels by reducing its hepatic clearance. 
• Oxcarbazepine: An enzyme inducer that may reduce Ivermectin plasma concentrations, potentially diminishing therapeutic efficacy. 
• Amprenavir: This HIV protease inhibitor may interfere with Ivermectin’s metabolic pathway, warranting clinical monitoring during concurrent use. 
• Antimalarial drugs: Research published in Malaria Journal (2025) indicates several antimalarial compounds metabolized by CYP3A4 — including lumefantrine, mefloquine, and pyronaridine — may notably affect Ivermectin metabolism when co-administered, relevant in endemic regions where co-administration may occur. 

Inform your healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and recreational substances before commencing Iverheal 3mg therapy. 

Clinical Examination and Monitoring 

Prior to initiating Iverheal 3mg, your healthcare provider may recommend specific diagnostic tests to confirm the parasitic diagnosis and establish a baseline for monitoring treatment response: 

Stool Examination 

For intestinal strongyloidiasis, stool microscopy is conducted before treatment to confirm the presence of Strongyloides larvae and after treatment to verify eradication. The FDA-approved Stromectol prescribing information specifically recommends follow-up stool examinations following completion of therapy. 

Skin Snip and Microfilariae Count 

For onchocerciasis, the microfilarial density in skin snips and ocular assessments is measured before and during treatment. A reduction in microfilarial count serves as a primary indicator of treatment success. If the count does not improve adequately, a dose adjustment or alternative regimen may be considered. 

Eye Examination 

Patients receiving Iverheal 3mg for ocular manifestations of parasitic disease require serial eye examinations to monitor for treatment-related ocular adverse events, including uveitis or optic neuritis. Persistent or worsening ocular side effects may necessitate a change in therapeutic approach. 

Liver Function Tests 

In patients with pre-existing hepatic conditions or those requiring prolonged therapy, periodic liver function testing is advisable to monitor for hepatotoxicity and to ensure appropriate drug metabolism. 

Storage Instructions 

• Store Iverheal 3mg below 30°C (86°F) in a cool, dry environment away from direct sunlight, heat, and moisture. 
• Keep the medication in its original packaging, tightly sealed after each use. 
• Store in a location inaccessible to children and pets at all times. 
• Check the expiry date on the packaging before use; do not administer medication beyond its stated shelf life. 
• Do not dispose of unused medications in wastewater or household refuse. Consult your pharmacist for guidance on safe pharmaceutical disposal. 

Frequently Asked Questions (FAQs) 

What is Iverheal 3mg used for? 

Iverheal 3mg is prescribed for the treatment of parasitic infections affecting the intestinal tract, skin, and eyes. Its primary approved indications include intestinal strongyloidiasis and onchocerciasis (river blindness). It is also used off-label for scabies, filariasis, head lice, cutaneous larva migrans, and Mansonella infections. 

Is Iverheal 3mg available over the counter? 

No. Iverheal 3mg is a prescription-only medication. It must not be used for self-medication. Always obtain a valid prescription from a qualified healthcare provider before purchasing or using this medication. 

How does Iverheal 3mg work? 

Iverheal 3mg works by selectively binding to glutamate-gated chloride ion channels found in invertebrate nerve and muscle cells. This causes hyperpolarization of the parasite’s cells, leading to paralysis and death. It also inhibits the production of larvae by adult female parasites. Because these channels do not exist in mammals, the drug is selectively toxic to parasites at therapeutic doses. 

Can I take Iverheal 3mg during pregnancy? 

Iverheal 3mg is generally not recommended during pregnancy, particularly in the first trimester. A systematic review published in The Lancet Global Health (2020) identified insufficient evidence to confirm its safety in pregnancy. Treatment should only be considered if clearly medically necessary, as assessed by a qualified healthcare provider. 

What happens if I miss a dose? 

Take the missed dose as soon as you remember, provided there is adequate time before the next scheduled dose. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not take two doses at the same time. 

What are the most important drug interactions with Iverheal 3mg? 

The most clinically significant interactions include Warfarin (increased bleeding risk), Erythromycin (elevated Ivermectin plasma levels), Oxcarbazepine (reduced Ivermectin efficacy), and Amprenavir (metabolic pathway interference). Always disclose all current medications to your healthcare provider before starting Iverheal 3mg. 

How should Iverheal 3mg be stored? 

Store below 30°C (86°F) in a dry, cool environment away from moisture, heat, and direct sunlight. Keep out of reach of children. Do not use after the expiry date printed on the label. 

References

• Drugs.com. (Updated January 2026). Ivermectin: Uses, Dosage, Side Effects, Warnings. https://www.drugs.com/ivermectin.html
• Drugs.com. (Updated January 2026). Ivermectin Dosage Guide — Stromectol. https://www.drugs.com/dosage/ivermectin.html
• Medical News Today. (Updated April 2026). Ivermectin dosage chart: How to take 3-mg oral tablets. https://www.medicalnewstoday.com/articles/drugs-ivermectin-dosage
• WebMD / Ethridge L, Riemann L. (Medically Reviewed August 2024). Ivermectin (Stromectol): Uses, Side Effects, Interactions, Warnings. https://www.webmd.com/drugs/2/drug-1122/ivermectin-oral/details
• Médecins Sans Frontières (MSF). (2024). Ivermectin Oral: MSF Medical Guidelines. https://medicalguidelines.msf.org/en/viewport/EssDr/english/ivermectin-oral-16683965.html
• Nicolas P, Maia MF, Bassat Q, et al. (2020). Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. The Lancet Global Health, 8(1), e92–e100. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613514/
• Tipthara P, Kullasakboonsri R, Kobylinski KC, Tarning J. (2025). Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds. Malaria Journal. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462173/
• Pérez de la Lastra JM, et al. (2025). Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12655129/